Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the... see more

TSX:RVX - Post Discussion

Resverlogix Corp > Canadian Covid pill potential Edmonton Journal Jan 18, 2022
View:
Post by doosomdo on Jan 21, 2022 1:54pm

Canadian Covid pill potential Edmonton Journal Jan 18, 2022

RVX.T    Published in Edmonton Journal  Jan 18th, 2022 go view for full article but here are some broad lines…
An Alberta-developed drug heralded as a potential oral treatment for COVID-19 has begun testing at Edmonton’s University of Alberta hospital.
Enrolment and dosing has already begun at the Edmonton hospital to evaluate the safety and effectiveness of apabetalone, Alberta-based Resverlogix Corp. announced in a Tuesday press release. A total of 100 patients are expected to be enrolled over the coming weeks at multiple sites in Canada, including Calgary and Toronto and four sites in Brazil, said Donald McCaffrey, president and CEO of Resverlogix.
Apabetalone has a unique dual mechanism that may help stop disease progression by regulating the expression of disease and inflammation-causing genes, McCaffrey explains, helping to restore gene expression to a healthier state, without altering DNA.
McCaffrey said the drug is affordable as well, with each pill costing around $7. He said patients would take two pills a day for a couple of weeks, a month at most. If the testing phase goes over well, McCaffrey hopes the pills can be prescribed to people when they are diagnosed with COVID-19 and before they have to enter the hospital as a patient at all.
Comment by QualityTest on Jan 21, 2022 10:22pm
"McCaffrey said the drug is affordable as well, with each pill costing around $7. He said patients would take two pills a day for a couple of weeks, a month at most. If the testing phase goes over well, McCaffrey hopes the pills can be prescribed to people when they are diagnosed with COVID-19 and before they have to enter the hospital as a patient at all." Interesting. The US trial was ...more  
Comment by narmac on Jan 22, 2022 7:54am
QT,,,,,,you cant be serious,,,,,,why would any shareholder take DMcC at his word,,,,,,good grief,,this man has absolutley no idea around research protocol or what takes place during a trial or for that matter what reason or when it does!!!,,,,listening to his gobblygook is the definition of insanity!!!,,now our future seems really to be decided by accident and ad hoc, supported by complacency of ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities